News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

February

21

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

DENVER and CHICAGO, February 21, 2023 – TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”),...

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes...

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

Studies evaluating methods to overcome two major challenges in treating patients with liver and...

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

Data further substantiates potential to significantly improve immunotherapy outcomes for patients with liver and...

14

TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation

Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive...

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

Studying the delivery of SD-101 via pressure-enabled drug delivery in adults with hepatocellular carcinoma...

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

Immunotherapeutic collaboration will advance efforts to develop new treatment options for patients with liver...

Recent developments

News

February

21

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

February

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

December

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

November

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

November

14

TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation

May

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

April

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus